No Data
No Data
No Data
No Data
No Data
Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(1.55) by 44.52 percent. This is a 75.43 percent increase over losses o
BenzingaApr 2 04:28
Press Release: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent operational highlights.
Dow JonesApr 2 04:15
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares traded lower by 7.2% to $0.17 Monday morning, hitting a new-all time low. The stock is trading lower on downward momentum after the company last
BenzingaApr 1 22:43
12 Health Care Stocks Moving In Friday's Intraday Session
GainersAvalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASD
BenzingaMar 30 00:30
Why Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliterated
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares are trading lower by 33.9% to $0.22 Thursday afternoon after the company announced the pricing of a $4.4 million registered direct offering.Toni
BenzingaMar 29 01:02
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering March 28, 2024 9:32am EDT Download as PDF CHATHAM, N.J., March 28, 2024
Tonix PharmaceuticalsMar 28 12:00
No Data
No Data